annual meeting program - American Society of Clinical Oncology
28.02.2013 • Views
Share Embed Flag

annual meeting program - American Society of Clinical Oncology

annual meeting program - American Society of Clinical Oncology

annual meeting program - American Society of Clinical Oncology

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
asco.org

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

START NOW

MONDAY<br />

Monday, June 7, 2010<br />

Brd. 16D Phase II trial <strong>of</strong> non pegylated liposomal doxorubicin and low-dose<br />

prednisone in second-line chemotherapy for hormone-refractory prostate<br />

cancer: A translational study. (Abstract #4683)<br />

M. Montanari, F. Fabbri, L. Frassineti, E. Rondini, R. Mattioli, S. Luzi Fedeli,<br />

D. Turci, S. Carloni, D. Amadori, G. Cruciani<br />

Brd. 16E Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate<br />

cancer (mCRPC): Results <strong>of</strong> a prospective randomized phase II trial <strong>of</strong> the<br />

DoD Prostate Cancer <strong>Clinical</strong> Trials Consortium. (Abstract #4684)<br />

E. J. Small, T. M. Beer, V. K. Weinberg, C. S. Higano, L. T. Nordquist,<br />

J. E. Rosenberg, J. J. Alumkal, E. Y. Yu, J. Sun, A. M. Lin<br />

Brd. 16F Nonmetastatic, high-risk prostate cancer patients with biochemical relapse<br />

after local treatment: A prospective, randomized phase III study comparing<br />

hormonal therapy �/� docetaxel: An analysis <strong>of</strong> final safety results.<br />

(Abstract #4685)<br />

S. Oudard, I. Latorzeff, P. Beuzeboc, A. Caty, E. Sevin, R. Delva, F. Rolland,<br />

L. Mourey, F. Priou, S. Culine<br />

Brd. 16G Influence <strong>of</strong> concurrent medications on outcomes <strong>of</strong> men with prostate<br />

cancer included in the TAX327 study. (Abstract #4686)<br />

S. Niraula, I. Tannock, G. R. Pond, R. De Wit, M. A. Eisenberger, A. M. Joshua<br />

Brd. 16H Efficacy and toxicity <strong>of</strong> docetaxel in elderly men with castrate-resistant<br />

metastatic prostate cancer. (Abstract #4687)<br />

D. R. Shepard, A. Weil, J. A. Garcia, R. Dreicer, D. Raghavan<br />

Brd. 17A A phase I study <strong>of</strong> combined docetaxel and repeated high activity rhenium-<br />

186-HEDP in castration resistant prostate cancer metastatic to bone<br />

(the TAXIUM trial). (Abstract #4688)<br />

J. M. van Dodewaard-de Jong, H. Bloemendal, J. M. de Klerk, B. P. van Bezooijen,<br />

M. J. de Haas, R. H. Wilson, J. M. O’Sullivan<br />

Brd. 17B Final results <strong>of</strong> a phase I study <strong>of</strong> CTLA-4 blockade in combination with<br />

GM-CSF for metastatic castration-resistant prostate cancer (mCRPC).<br />

(Abstract #4689)<br />

A. L. Harzstark, L. Fong, V. K. Weinberg, C. J. Ryan, A. M. Lin, J. Sun, E. J. Small<br />

Brd. 17C Correcting overall survival (OS) effect for the impact <strong>of</strong> cross-over via rank<br />

preserving structural failure time (RPSFT) model: Case <strong>of</strong> mRCC RECORD-1<br />

trial <strong>of</strong> everolimus (EVE). (Abstract #4690)<br />

E. Zuber, P. Korhonen, M. Branson, N. Hollaender, T. Katiskalahti, D. E. Lebwohl,<br />

T. Haas<br />

368

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!